BAYER AG
π©πͺGermany
- Country
- π©πͺGermany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Non-interventional Study on Oral Contraception Not Containing Ethinylestradiol (EE) to Assess Continuation Rates and Satisfaction
Completed
- Conditions
- Contraceptives, Oral
- Interventions
- Drug: EV/DNG (Qlaira, BAY86-5027)Drug: Progestin Only Pills
- First Posted Date
- 2010-09-13
- Last Posted Date
- 2015-10-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 3258
- Registration Number
- NCT01200186
Study to Investigate Adherence of Patients to Clodronate (Bonefos) Treatment
Completed
- Conditions
- Breast NeoplasmsProstatic NeoplasmsMultiple MyelomaOsteolysis
- Interventions
- First Posted Date
- 2010-09-10
- Last Posted Date
- 2012-09-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 147
- Registration Number
- NCT01198457
To Evaluate Compliance to Treatment Regimen (Rate of Deviations From the Prescribed Regimen) in Polish Females Treated With Different Low Dose Oral Contraceptives
Completed
- Conditions
- Contraception
- Interventions
- Drug: EE/DRSP (Yasmin Product Family)
- First Posted Date
- 2010-09-10
- Last Posted Date
- 2011-11-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 11884
- Registration Number
- NCT01198444
Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy
- First Posted Date
- 2010-09-06
- Last Posted Date
- 2019-06-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 11
- Registration Number
- NCT01195649
GIDEON Non-Nexavar Arm - HCC Patients Who Are Treated With Any Therapy Other Than Nexavar at Individual Study Start
Withdrawn
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Drug: Any treatment for unresectable HCC as chosen by the physician
- First Posted Date
- 2010-08-30
- Last Posted Date
- 2017-08-16
- Lead Sponsor
- Bayer
- Registration Number
- NCT01191385
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies
- First Posted Date
- 2010-08-25
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 112
- Registration Number
- NCT01188252
Long-term Study in Chronic Kidney Disease (Extension From Study 14817)
Phase 3
Completed
- Conditions
- Hyperphosphatemia
- Interventions
- First Posted Date
- 2010-08-24
- Last Posted Date
- 2015-04-03
- Lead Sponsor
- Bayer
- Target Recruit Count
- 123
- Registration Number
- NCT01187628
Determination of Safety, Efficacy, and Pharmacokinetics of "Regorafenib" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung Cancer
Phase 1
Terminated
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2010-08-24
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 9
- Registration Number
- NCT01187615
Data on Oral Contraceptives Compliance in Non Stop Regimen
Completed
- Conditions
- Contraception
- Interventions
- Drug: Qlaira or Yaz (BSP products defined as Combined Oral Contraceptive) and Cerazette or Azalia (competitor's products defined as Progestogen Only Pill)
- First Posted Date
- 2010-08-20
- Last Posted Date
- 2013-06-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 8416
- Registration Number
- NCT01185678
Evaluation of Risk Factors for Early Termination of Injection Treatment With Betaferon in Patients Suffering From Multiple Sclerosis
- First Posted Date
- 2010-08-19
- Last Posted Date
- 2013-06-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 852
- Registration Number
- NCT01184833
Β© Copyright 2025. All Rights Reserved by MedPath